NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Oracle Corp. (ORCL) shares jumped 13.3% after reporting fourth-quarter fiscal 2025 adjusted earnings per share of $1.70, surpassing the Zacks Consensus Estimate of $1.64. Shares of Alphabet Inc.

Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...

COPENHAGEN] Novo Nordisk reclaimed its position as Europe’s most valuable public company, overtaking software developer SAP. Read more at The Business Times.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The decision to advance the study of subcutaneous and oral Amycretin into the late stage is based on feedback received from ...

Novo Nordisk (NYSE: NVO) announced Thursday it will initiate Phase 3 trials for its experimental weight-loss drug amycretin in both injection and oral forms during the first quarter of 2026. The ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...